Serum soluble Fas and FasL levels in elderly patients with skin cancer and their clinical significance
10.3760/cma.j.cn115455-20191030-00844
- VernacularTitle:老年皮肤癌患者血清可溶性Fas、FasL水平及临床意义
- Author:
Keyu YUAN
1
;
Yu JI
Author Information
1. 浙江省诸暨市人民医院外科 311800
- From:
Chinese Journal of Postgraduates of Medicine
2020;43(4):317-320
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the serum levels of soluble Fas (sFas) and soluble FasL (sFasL) in elderly patients with skin cancer and its clinical significance.Methods:Eighty-two elderly skin cancer patients who underwent surgical treatment in Zhuji People′s Hospital and Zhejiang Provincial People′s Hospital from January 2014 to December 2017 were selected as the skin cancer group, and 82 healthy elderly patients were selected as the control group. The serum sFas and sFasL levels were determined by double anti sandwich enzyme linked immunosorbent assay (ELISA).Results:The serum levels of sFas and sFasL in the skin cancer group were higher than those in the control group [(21.06 ± 3.23) μg/L vs. (5.64 ± 1.18) μg/L, (14.52 ± 3.42) μg/L vs.(3.27 ± 0.96) μg/L], there were significant differences ( t=40.606, 28.679, P<0.05). The serum sFas and sFasL levels were closely related to pathological grade and lymph node metastasis. The serum levels of sFas and sFasL in patients with pathological grade Ⅲ-Ⅳ were higher than those at grade Ⅰ-Ⅱ [(23.57 ± 3.16) μg/L vs. (16.35 ± 3.62) μg/L, (17.16 ± 3.29) μg/L vs. (12.15 ± 3.58) μg/L], there were significant differences ( t=8.931, 6.173, P<0.05). The serum levels of sFas and sFasL in patients with lymph node metastasis were higher than those without lymph node metastasis [(24.09 ± 3.46) μg/L vs. (14.37 ± 3.19) μg/L, (18.17 ± 3.64) μg/L vs. (11.02 ± 3.27) μg/L], there were significant differences ( t=13.124, 9.306, P<0.05). The serum sFas and sFasL levels were not associated with age, gender, location and type ( P>0.05). The serum sFas and sFasL levels after treatment were lower in patients with skin cancer than before treatment [(7.94 ± 1.21) μg/L vs. (21.06 ± 3.23) μg/L, (5.38 ± 1.02) μg/L vs. (14.52 ± 3.42) μg/L], there were significant differences ( t=34.445, 23.191, P<0.05). Conclusions:Serum sFas and sFasL levels are elevated in elderly skin cancer patients. The serum sFas and sFasL levels are closely related to pathological grade and lymph node metastasis in elderly skin cancer patients, and the clinical efficacy can be evaluated.
